CLINICAL TRIALS PROFILE FOR LOPINAVIR; RITONAVIR
✉ Email this page to a colleague
505(b)(2) Clinical Trials for LOPINAVIR; RITONAVIR
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT00196625 ↗ | Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure. | Completed | French National Agency for Research on AIDS and Viral Hepatitis | Phase 2 | 2000-11-01 | HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for LOPINAVIR; RITONAVIR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004578 ↗ | ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects | Completed | Abbott | Phase 1/Phase 2 | 1997-11-01 | To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects. |
| NCT00006144 ↗ | A Study of HIV-Disease Development in Aging | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2000-10-01 | The purpose of this study is to better understand the relationship between age and HIV disease progression. This study will explore the possible relationship between age and HIV disease progression. Older age is an important risk factor for faster disease development, but older people may respond better to combination drug therapy. This relationship needs to be understood better. |
| NCT00014937 ↗ | Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 1969-12-31 | ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen. This study will compare the ability of two different three-drug anti-HIV drug regimens to reduce levels of HIV in the blood. The study will also evaluate whether patients discontinue the regimens because of drug side effects. |
| NCT00017992 ↗ | Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV | Unknown status | Triangle Pharmaceuticals | Phase 2 | 1969-12-31 | The purpose of this study is to see if emtricitabine is safe in children infected with HIV and to determine the best dose. |
| NCT00023218 ↗ | Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 1969-12-31 | The purpose of this study is to look at how 2 different anti-HIV drug treatments affect the liver. The use of anti-HIV drugs like the nucleoside reverse transcriptase inhibitors (NRTIs) may be linked to liver problems like fatty changes, scarring, abnormal liver function tests (LFTs), and lactic acidemia (an increase in lactic acid in the blood). Increased liver enzymes may mean liver damage. The way that the liver changes in people with abnormal LFTs and lactic acidemia is not completely understood. |
| NCT00025727 ↗ | Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure | Unknown status | GlaxoSmithKline | Phase 3 | 2001-05-01 | The purpose of this study is to test 2 different dosing regimens of GW433908/ritonavir (RTV) versus lopinavir (LPV)/RTV when each is given with 2 active reverse transcriptase inhibitors (RTIs), in patients who have taken anti-HIV drugs without success. |
| NCT00027339 ↗ | Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 1969-12-31 | Because people infected with HIV strains that are resistant to anti-HIV drugs have fewer effective treatment options, selecting an effective anti-HIV drug combination is difficult. A combination of protease inhibitors (PIs), when added to a patient's current anti-HIV therapy, may decrease viral load and increase drug activity. Tests that measure drug levels in the blood and tests to evaluate the drug resistance of HIV may also be helpful in choosing the best anti-HIV drug combination for a patient. This study will determine whether using these tests to choose a drug combination and adding PIs to that combination will improve the patient's response to anti-HIV therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LOPINAVIR; RITONAVIR
Condition Name
Clinical Trial Locations for LOPINAVIR; RITONAVIR
Trials by Country
Clinical Trial Progress for LOPINAVIR; RITONAVIR
Clinical Trial Phase
Clinical Trial Sponsors for LOPINAVIR; RITONAVIR
Sponsor Name
| Sponsor Name for LOPINAVIR; RITONAVIR | |
| Sponsor | Trials |
| Abbott | 55 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 52 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 20 |
| [disabled in preview] | 50 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
